Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.

@article{Gallagher2001PreventionOB,
  title={Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.},
  author={John Christopher Gallagher and David J. Baylink and Ruth Freeman and Michael R Mcclung},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2001},
  volume={86 10},
  pages={4717-26}
}
Tibolone, a novel compound with tissue-specific effects, has been found to have antiresorptive properties in bone. To confirm the efficacy of tibolone and determine its minimum effective dose for prevention of bone loss in early postmenopausal women, two randomized, double-blind, placebo-controlled, dose-finding studies were performed. Seven hundred seventy healthy women postmenopausal within 1-4 yr, with normal bone density for their age, were treated for 2 yr with 0.3, 0.625, 1.25, or 2.5 mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Intracrinology: the secret of the tissue-specificity of tibolone

  • HJ Kloosterboer, R Sands
  • J Brit Menopause Soc
  • 2000
2 Excerpts

The effect of Livial at the mammary gland. Mammographic and hypermicroscopic findings

  • N Klearchou, M Kanallaki-Kyparissi, F Deligeorgi, M Koliakou, V Karagiannis, M Mamopoulos
  • The 9th International Menopause Society World…
  • 1999

Similar Papers

Loading similar papers…